CN108395482B - 一种靶向cd20抗原嵌合抗原受体的构建及其工程化t细胞的活性鉴定 - Google Patents

一种靶向cd20抗原嵌合抗原受体的构建及其工程化t细胞的活性鉴定 Download PDF

Info

Publication number
CN108395482B
CN108395482B CN201710069569.7A CN201710069569A CN108395482B CN 108395482 B CN108395482 B CN 108395482B CN 201710069569 A CN201710069569 A CN 201710069569A CN 108395482 B CN108395482 B CN 108395482B
Authority
CN
China
Prior art keywords
ser
gly
leu
val
pro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201710069569.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN108395482A (zh
Inventor
姚意弘
黄家琪
朱恃贵
朱蔚
姚昕
李志远
张丽
朱琳
马安云
魏雨恬
李延峰
王庆霞
何佳平
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Xibiman Biotechnology Group
Original Assignee
Cellular Biomedicine Group HK Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to CN201710069569.7A priority Critical patent/CN108395482B/zh
Application filed by Cellular Biomedicine Group HK Ltd filed Critical Cellular Biomedicine Group HK Ltd
Priority to HRP20230150TT priority patent/HRP20230150T1/hr
Priority to FIEP18751050.8T priority patent/FI3599251T3/fi
Priority to PT187510508T priority patent/PT3599251T/pt
Priority to ES18751050T priority patent/ES2936474T3/es
Priority to SM20230059T priority patent/SMT202300059T1/it
Priority to JP2019563660A priority patent/JP6918145B2/ja
Priority to US16/484,482 priority patent/US11066457B2/en
Priority to LTEPPCT/CN2018/075867T priority patent/LT3599251T/lt
Priority to PCT/CN2018/075867 priority patent/WO2018145649A1/zh
Priority to PL18751050.8T priority patent/PL3599251T3/pl
Priority to HUE18751050A priority patent/HUE061346T2/hu
Priority to EP18751050.8A priority patent/EP3599251B1/en
Priority to SI201830854T priority patent/SI3599251T1/sl
Priority to EP22206642.5A priority patent/EP4194473A1/en
Priority to RS20230128A priority patent/RS64106B1/sr
Priority to DK18751050.8T priority patent/DK3599251T5/da
Publication of CN108395482A publication Critical patent/CN108395482A/zh
Application granted granted Critical
Publication of CN108395482B publication Critical patent/CN108395482B/zh
Priority to US17/352,915 priority patent/US11472858B2/en
Priority to JP2021119965A priority patent/JP7241133B2/ja
Priority to US17/723,859 priority patent/US11618778B2/en
Priority to US17/750,855 priority patent/US11608369B2/en
Priority to US17/831,637 priority patent/US20220340640A1/en
Priority to US18/173,187 priority patent/US20230242613A1/en
Priority to JP2023033593A priority patent/JP7571178B2/ja
Priority to JP2024176918A priority patent/JP7767549B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4221—CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN201710069569.7A 2017-02-08 2017-02-08 一种靶向cd20抗原嵌合抗原受体的构建及其工程化t细胞的活性鉴定 Active CN108395482B (zh)

Priority Applications (25)

Application Number Priority Date Filing Date Title
CN201710069569.7A CN108395482B (zh) 2017-02-08 2017-02-08 一种靶向cd20抗原嵌合抗原受体的构建及其工程化t细胞的活性鉴定
RS20230128A RS64106B1 (sr) 2017-02-08 2018-02-08 Konstrukcija himernog antigenskog receptora koji ciljno deluje na cd20 antigen i identifikacija aktivnosti njegovih projektovanih t ćelija
PT187510508T PT3599251T (pt) 2017-02-08 2018-02-08 Construção do recetor de antigénio quimérico direcionado para o antigénio cd20 e identificação da atividade das células t modificadas do mesmo
ES18751050T ES2936474T3 (es) 2017-02-08 2018-02-08 Construcción del receptor de antígeno quimérico dirigido al antígeno cd20 y actividad identificación de las células T modificadas del mismo
SM20230059T SMT202300059T1 (it) 2017-02-08 2018-02-08 Costruzione di un recettore chimerico per l’antigene mirato a un antigene cd20 e identificazione dell’attività delle relative cellule t ingegnerizzate
JP2019563660A JP6918145B2 (ja) 2017-02-08 2018-02-08 Ｃｄ２０抗原を標的とするキメラ抗原受容体の構築およびその遺伝子改変ｔ細胞の活性同定
US16/484,482 US11066457B2 (en) 2017-02-08 2018-02-08 Construction of chimeric antigen receptor targeting CD20 antigen and activity identification of engineered T cells thereof
LTEPPCT/CN2018/075867T LT3599251T (lt) 2017-02-08 2018-02-08 Chimerinio antigeno receptoriaus, nukreipiamo į cd20 antigeną, konstravimas ir jo suformuotų t ląstelių aktyvumo identifikavimas
PCT/CN2018/075867 WO2018145649A1 (zh) 2017-02-08 2018-02-08 一种靶向cd20抗原嵌合抗原受体的构建及其工程化t细胞的活性鉴定
PL18751050.8T PL3599251T3 (pl) 2017-02-08 2018-02-08 Konstrukcja chimerycznego receptora antygenowego ukierunkowanego na antygen cd20 i identyfikacja aktywności zmodyfikowanych w ten sposób limfocytów t
HUE18751050A HUE061346T2 (hu) 2017-02-08 2018-02-08 CD20 antigént célzó kiméra antigén receptor elõállítása és az ebbõl elõállított T-sejtek aktivitásának azonosítása
FIEP18751050.8T FI3599251T3 (fi) 2017-02-08 2018-02-08 Cd20-antigeeniin kohdentuvan kimeerisen antigeenireseptorin rakentaminen ja sillä muunnettujen t-solujen aktiivisuuden tunnistaminen
HRP20230150TT HRP20230150T1 (hr) 2017-02-08 2018-02-08 Konstrukcija kimernog antigenskog receptora koji cilja cd20 antigen i identifikacija aktivnosti njegovih inženjerskih t-stanica
EP22206642.5A EP4194473A1 (en) 2017-02-08 2018-02-08 Construction of chimeric antigen receptor targeting cd20 antigen and activity identification of engineered t cells thereof
SI201830854T SI3599251T1 (sl) 2017-02-08 2018-02-08 Konstrukcija kimernega antigenskega receptorja, ciljnega na antigen CD20, in identifikacija aktivnosti njegovih inženiriranih T-celic
EP18751050.8A EP3599251B1 (en) 2017-02-08 2018-02-08 Construction of chimeric antigen receptor targeting cd20 antigen and activity identification of engineered t cells thereof
DK18751050.8T DK3599251T5 (da) 2017-02-08 2018-02-08 Konstruktion af kimær antigenreceptor, der er målrettet mod cd20-antigen, og aktivitetsidentifikation af genmanipulerede t-celler deraf
US17/352,915 US11472858B2 (en) 2017-02-08 2021-06-21 Construction of chimeric antigen receptor targeting CD20 antigen and activity identification of engineered T cells thereof
JP2021119965A JP7241133B2 (ja) 2017-02-08 2021-07-20 Ｃｄ２０抗原を標的とするキメラ抗原受容体の構築およびその遺伝子改変ｔ細胞の活性同定
US17/723,859 US11618778B2 (en) 2017-02-08 2022-04-19 Construction of chimeric antigen receptor targeting CD20 antigen and activity identification of engineered T cells thereof
US17/750,855 US11608369B2 (en) 2017-02-08 2022-05-23 Construction of chimeric antigen receptor targeting CD20 antigen and activity identification of engineered T cells thereof
US17/831,637 US20220340640A1 (en) 2017-02-08 2022-06-03 Construction of chimeric antigen receptor targeting cd20 antigen and activity identification of engineered t cells thereof
US18/173,187 US20230242613A1 (en) 2017-02-08 2023-02-23 Construction of chimeric antigen receptor targeting cd20 antigen and activity identification of engineered t cells thereof
JP2023033593A JP7571178B2 (ja) 2017-02-08 2023-03-06 Ｃｄ２０抗原を標的とするキメラ抗原受容体の構築およびその遺伝子改変ｔ細胞の活性同定
JP2024176918A JP7767549B2 (ja) 2017-02-08 2024-10-09 Ｃｄ２０抗原を標的とするキメラ抗原受容体の構築およびその遺伝子改変ｔ細胞の活性同定

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201710069569.7A CN108395482B (zh) 2017-02-08 2017-02-08 一种靶向cd20抗原嵌合抗原受体的构建及其工程化t细胞的活性鉴定

Publications (2)

Publication Number Publication Date
CN108395482A CN108395482A (zh) 2018-08-14
CN108395482B true CN108395482B (zh) 2021-02-05

Family

ID=63094096

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201710069569.7A Active CN108395482B (zh) 2017-02-08 2017-02-08 一种靶向cd20抗原嵌合抗原受体的构建及其工程化t细胞的活性鉴定

Country Status (16)

Country Link
US (6) US11066457B2 (enExample)
EP (2) EP4194473A1 (enExample)
JP (4) JP6918145B2 (enExample)
CN (1) CN108395482B (enExample)
DK (1) DK3599251T5 (enExample)
ES (1) ES2936474T3 (enExample)
FI (1) FI3599251T3 (enExample)
HR (1) HRP20230150T1 (enExample)
HU (1) HUE061346T2 (enExample)
LT (1) LT3599251T (enExample)
PL (1) PL3599251T3 (enExample)
PT (1) PT3599251T (enExample)
RS (1) RS64106B1 (enExample)
SI (1) SI3599251T1 (enExample)
SM (1) SMT202300059T1 (enExample)
WO (1) WO2018145649A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12129304B2 (en) 2017-10-19 2024-10-29 F. Hoffmann-La Roche Ag Treatment of CD20-positive B-cell lymphoma with obinutuzumab

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3656977T3 (pl) 2012-09-14 2024-03-04 Joy Global Underground Mining Llc Głowica wrębiarki do maszyny górniczej
CN108395482B (zh) * 2017-02-08 2021-02-05 西比曼生物科技（香港）有限公司 一种靶向cd20抗原嵌合抗原受体的构建及其工程化t细胞的活性鉴定
CN111201030B (zh) 2017-07-25 2024-11-01 真和制药有限公司 通过阻断tim-3和其配体的相互作用治疗癌症
CN112955172A (zh) * 2018-09-17 2021-06-11 美国卫生和人力服务部 靶向cd19和cd20的双顺反子嵌合抗原受体及其用途
JP7386382B2 (ja) 2018-12-12 2023-11-27 カイト ファーマ インコーポレイテッド キメラ抗原受容体及びｔ細胞受容体並びに使用方法
CN109593137B (zh) * 2018-12-29 2023-04-14 博生吉医药科技(苏州)有限公司 抗cd20抗体的新型cd20-car载体的构建及应用
EP3918323A4 (en) 2019-01-30 2022-12-28 TrueBinding, Inc. ANTI-GAL3 ANTIBODIES AND USES THEREOF
WO2021174124A1 (en) * 2020-02-27 2021-09-02 Sorrento Therapeutics, Inc. Dimeric antigen receptors (dar) that bind cd20
CN113402612A (zh) * 2020-03-17 2021-09-17 西比曼生物科技（香港）有限公司 靶向cd19和cd20的联合嵌合抗原受体及其应用
WO2021242776A2 (en) 2020-05-26 2021-12-02 Truebinding, Inc. Methods of treating inflammatory diseases by blocking galectin-3
KR20230122618A (ko) 2020-12-21 2023-08-22 알로젠 테라퓨틱스 인코포레이티드 프로테아제 활성화 cd45-게이트 car
WO2022164886A2 (en) * 2021-01-27 2022-08-04 Cellular Biomedicine Group Hk Limited Chimeric antigen receptors targeting cd20
WO2022165233A1 (en) 2021-01-29 2022-08-04 Allogene Therapeutics, Inc. KNOCKDOWN OR KNOCKOUT OF ONE OR MORE OF TAP2, NLRC5, β2m, TRAC, RFX5, RFXAP AND RFXANK TO MITIGATE T CELL RECOGNITION OF ALLOGENEIC CELL PRODUCTS
IL309957A (en) 2021-07-14 2024-03-01 2Seventy Bio Inc Engineered t cell receptors fused to binding domains from antibodies
EP4408442A4 (en) * 2021-10-01 2025-10-29 Univ Texas Immune cells loaded with antibodies and their methods of use in cancer treatment
WO2023196997A2 (en) 2022-04-08 2023-10-12 2Seventy Bio, Inc. Multipartite receptor and signaling complexes
CN117003872A (zh) * 2022-04-28 2023-11-07 北京天广实生物技术股份有限公司 含有突变轻链可变区骨架的单链抗体片段
EP4562134A1 (en) 2022-07-29 2025-06-04 Allogene Therapeutics, Inc. Engineered cells with reduced gene expression to mitigate immune cell recognition
EP4626447A1 (en) 2023-03-31 2025-10-08 AbelZeta Inc. Bispecific chimeric antigen receptors targeting cd20 and bcma
WO2025059162A1 (en) 2023-09-11 2025-03-20 Dana-Farber Cancer Institute, Inc. Car-engager containing il-2 variants to enhance the functionality of car t cells
WO2025096560A1 (en) 2023-10-30 2025-05-08 Allogene Therapeutics, Inc. Engineered cells
WO2025097041A1 (en) * 2023-11-03 2025-05-08 Board Of Regents, The University Of Texas System Methods for the detection and treatment of resistant cancers co-expressing alpp and/or alpg/alppl2

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101544694A (zh) * 2008-03-28 2009-09-30 上海中信国健药业有限公司 抗cd20四价抗体、其制备方法和应用
CN106279434A (zh) * 2014-02-24 2017-01-04 西比曼生物科技（上海）有限公司 工程化cd20靶向性的nkt细胞及其制备方法和应用

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
US5350674A (en) 1992-09-04 1994-09-27 Becton, Dickinson And Company Intrinsic factor - horse peroxidase conjugates and a method for increasing the stability thereof
TWI239352B (en) 1997-07-23 2005-09-11 Takara Bio Inc Gene transfer method with the use of serum-free medium
US6410319B1 (en) 1998-10-20 2002-06-25 City Of Hope CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies
WO2001029058A1 (en) 1999-10-15 2001-04-26 University Of Massachusetts Rna interference pathway genes as tools for targeted genetic interference
US6326193B1 (en) 1999-11-05 2001-12-04 Cambria Biosciences, Llc Insect control agent
WO2001096584A2 (en) 2000-06-12 2001-12-20 Akkadix Corporation Materials and methods for the control of nematodes
US8287864B2 (en) 2002-02-14 2012-10-16 Immunomedics, Inc. Structural variants of antibodies for improved therapeutic characteristics
PL216630B1 (pl) * 2002-10-17 2014-04-30 Genmab As Izolowane ludzkie przeciwciało monoklonalne wiążące ludzki CD20, związane z tym przeciwciałem transfektoma, komórka gospodarza, transgeniczne zwierzę lub roślina, kompozycja, immunokoniugat, cząsteczka bispecyficzna, wektor ekspresyjny, kompozycja farmaceutyczna, zastosowanie medyczne, zestaw oraz przeciwciało antyidiotypowe i jego zastosowanie
KR101229731B1 (ko) * 2003-10-16 2013-03-07 암젠 리서치 (뮌헨) 게엠베하 다중특이적 탈면역화된 ｃｄ3-바인더
US7435596B2 (en) 2004-11-04 2008-10-14 St. Jude Children's Research Hospital, Inc. Modified cell line and method for expansion of NK cell
JP2009539413A (ja) * 2006-06-12 2009-11-19 トゥルビオン・ファーマシューティカルズ・インコーポレーテッド エフェクター機能を有する単鎖多価結合タンパク質
US20130004480A1 (en) * 2006-07-04 2013-01-03 Paul Parren CD20 Binding Molecules for the Treatment of Copd
CN101990439A (zh) * 2007-07-06 2011-03-23 特鲁比昂药品公司 具有置于c末端的特异性结合结构域的结合肽
ME00973B (me) 2007-07-31 2012-06-20 Regeneron Pharma Humana antitjela prema humanom cd20 i postupak njihovog korišćenja
US20110091473A1 (en) * 2007-10-22 2011-04-21 Genmab A/S Novel antibody therapies
AU2013221672B2 (en) * 2012-02-13 2017-11-09 Seattle Children's Hospital D/B/A Seattle Children's Research Institute Bispecific chimeric antigen receptors and therapeutic uses thereof
CN104640562A (zh) * 2012-07-13 2015-05-20 酵活有限公司 包含抗-cd3构建体的双特异性不对称异二聚体
JP2015092865A (ja) * 2013-11-13 2015-05-18 国立大学法人名古屋大学 ヒト化抗ｃｄ２０キメラ抗原レセプター
US20160333108A1 (en) 2014-01-13 2016-11-17 Stephen J. Forman CHIMERIC ANTIGEN RECEPTORS (CARs) HAVING MUTATIONS IN THE FC SPACER REGION AND METHODS FOR THEIR USE
EP3722316A1 (en) * 2014-07-21 2020-10-14 Novartis AG Treatment of cancer using a cd33 chimeric antigen receptor
EP3227323B1 (en) 2014-12-03 2020-08-05 Juno Therapeutics, Inc. Methods and compositions for adoptive cell therapy
WO2016100232A1 (en) * 2014-12-15 2016-06-23 The Regents Of The University Of California Bispecific or-gate chimeric antigen receptor responsive to cd19 and cd20
CA2969384A1 (en) * 2014-12-17 2016-06-23 Cellectis Inhibitory chimeric antigen receptor (icar or n-car) expressing non-t cell transduction domain
WO2016126950A1 (en) * 2015-02-05 2016-08-11 Molecular Templates, Inc. Multivalent cd20-binding molecules comprising shiga toxin a subunit effector regions and enriched compositions thereof
MA41613A (fr) * 2015-02-23 2018-01-02 Abbvie Stemcentrx Llc Récepteurs antigéniques chimériques anti-dll3 et procédés d'utilisation desdits récepteurs
BR112017021500A2 (pt) * 2015-04-08 2018-09-25 Novartis Ag terapias com cd20, terapias com cd22 e terapias de combinação com uma célula que expressa (car) receptor de antígeno quimérico de cd19
GB201506223D0 (en) * 2015-04-13 2015-05-27 Ucl Business Plc Chimeric protein
CN105384825B (zh) * 2015-08-11 2018-06-01 南京传奇生物科技有限公司 一种基于单域抗体的双特异性嵌合抗原受体及其应用
MA43135A (fr) * 2015-10-30 2018-09-05 Aleta Biotherapeutics Inc Compositions et méthodes pour le du traitement du cancer
NZ744913A (en) * 2016-03-18 2025-09-26 Fred Hutchinson Cancer Center Compositions and methods for cd20 immunotherapy
TWI691596B (zh) 2016-04-01 2020-04-21 美商凱特製藥公司 嵌合抗原和ｔ細胞受體及使用方法
US10525083B2 (en) * 2016-10-07 2020-01-07 Novartis Ag Nucleic acid molecules encoding chimeric antigen receptors comprising a CD20 binding domain
CN108395482B (zh) * 2017-02-08 2021-02-05 西比曼生物科技（香港）有限公司 一种靶向cd20抗原嵌合抗原受体的构建及其工程化t细胞的活性鉴定
CR20190431A (es) 2017-03-27 2019-11-01 Hoffmann La Roche Formatos mejorados de receptor de unión a antígeno
EP3710471A1 (en) 2017-11-16 2020-09-23 Kite Pharma, Inc. Modified chimeric antigen receptors and methods of use
CN109971725B (zh) 2017-12-28 2024-02-02 上海细胞治疗研究院 抗体修饰的嵌合抗原受体修饰t细胞及其用途
US12036242B2 (en) 2018-07-05 2024-07-16 H. Lee Moffitt Cancer Center And Research Institute, Inc. CAR T cells that target B-cell antigens
TWI739358B (zh) * 2019-03-25 2021-09-11 免疫功坊股份有限公司 帶有金屬結合區的複合多肽及其分子構建體
CN113402612A (zh) 2020-03-17 2021-09-17 西比曼生物科技（香港）有限公司 靶向cd19和cd20的联合嵌合抗原受体及其应用

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101544694A (zh) * 2008-03-28 2009-09-30 上海中信国健药业有限公司 抗cd20四价抗体、其制备方法和应用
CN106279434A (zh) * 2014-02-24 2017-01-04 西比曼生物科技（上海）有限公司 工程化cd20靶向性的nkt细胞及其制备方法和应用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Preserved Activity of CD20-Specific Chimeric Antigen Receptor-Expressing T cells in the Presence of Rituximab;RUFENER, G.A.等;《Cancer Immunol Res.》;20160630;第4卷(第6期);摘要，第3-4页 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12129304B2 (en) 2017-10-19 2024-10-29 F. Hoffmann-La Roche Ag Treatment of CD20-positive B-cell lymphoma with obinutuzumab

Also Published As

Publication number Publication date
JP6918145B2 (ja) 2021-08-11
JP2020508077A (ja) 2020-03-19
EP3599251A4 (en) 2020-11-18
EP4194473A1 (en) 2023-06-14
US11066457B2 (en) 2021-07-20
JP7571178B2 (ja) 2024-10-22
LT3599251T (lt) 2023-03-10
DK3599251T5 (da) 2024-09-02
US20200002400A1 (en) 2020-01-02
FI3599251T3 (fi) 2023-03-08
US20230242613A1 (en) 2023-08-03
HRP20230150T1 (hr) 2023-04-14
ES2936474T3 (es) 2023-03-17
CN108395482A (zh) 2018-08-14
SMT202300059T1 (it) 2023-03-17
JP2025004176A (ja) 2025-01-14
US11618778B2 (en) 2023-04-04
RS64106B1 (sr) 2023-04-28
EP3599251A1 (en) 2020-01-29
WO2018145649A1 (zh) 2018-08-16
US20220324940A1 (en) 2022-10-13
JP2023071892A (ja) 2023-05-23
US20220281945A1 (en) 2022-09-08
US11608369B2 (en) 2023-03-21
US11472858B2 (en) 2022-10-18
JP7241133B2 (ja) 2023-03-16
HUE061346T2 (hu) 2023-06-28
JP2022023023A (ja) 2022-02-07
US20210361710A1 (en) 2021-11-25
DK3599251T3 (da) 2023-02-20
US20220340640A1 (en) 2022-10-27
SI3599251T1 (sl) 2023-04-28
EP3599251B1 (en) 2022-11-16
PT3599251T (pt) 2023-02-28
PL3599251T3 (pl) 2023-06-26
JP7767549B2 (ja) 2025-11-11

Similar Documents

Publication Publication Date Title
CN108395482B (zh) 一种靶向cd20抗原嵌合抗原受体的构建及其工程化t细胞的活性鉴定
KR102520550B1 (ko) Cd19 및 cd20을 표적화하는 조합된 키메라 항원 수용체 및 그의 적용
JP7148611B2 (ja) Ｂｃｍａを標的とするキメラ抗原受容体およびその製造方法と使用
CN110950953A (zh) 抗b7-h3的单克隆抗体及其在细胞治疗中的应用
CN108395481B (zh) 一种靶向cd20的car的构建及其工程化t细胞的活性鉴定
CN111587254B (zh) 包含抗cd38和抗cd138嵌合抗原受体的t-细胞及其用途
CN107936120A (zh) Cd19靶向性的嵌合抗原受体及其制法和应用
EP4284824A2 (en) Chimeric antigen receptors targeting cd20
WO2022151959A1 (zh) 靶向b7-h3的car-t细胞及其在急性髓系白血病治疗中的应用
US20240115605A1 (en) Chimeric antigen receptors targeting cd20
WO2021208750A1 (zh) 靶向cd22的嵌合抗原受体及其制法和应用
HK40092581A (en) Construction of chimeric antigen receptor targeting cd20 antigen and activity identification of engineered t cells thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20201130

Address after: Room 417, 4 / F, tower 2, Lippo centre, 89 Queensway, Hong Kong, China

Applicant after: CELLULAR BIOMEDICINE GROUP HK Ltd.

Address before: 200233, building 1, building 333, No. 5, Guiping Road, Shanghai, Xuhui District

Applicant before: Cellular Biomedicine Group (Shanghai) Ltd.

Applicant before: CELLULAR BIOMEDICINE GROUP (WUXI) Ltd.

GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20221025

Address after: Building 3, No. 85 Faraday Road, Pudong New Area (Shanghai) Pilot Free Trade Zone, Shanghai

Patentee after: SHANGHAI CELLULAR BIOPHARMACEUTICAL Group Ltd.

Address before: Room 417, 4 / F, tower 2, Lippo centre, 89 Queensway, Hong Kong, China

Patentee before: CELLULAR BIOMEDICINE GROUP HK Ltd.

TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20231114

Address after: Maryland, USA

Patentee after: Xibiman Biotechnology Group

Address before: 201210 Building 3, No. 85 Faraday Road, Pudong New Area (Shanghai) Pilot Free Trade Zone, Shanghai

Patentee before: SHANGHAI CELLULAR BIOPHARMACEUTICAL Group Ltd.